Log in

Relevant bibliographies by topics / Prjt / Journal articles

To see the other types of publications on this topic, follow the link: Prjt.

Journal articles on the topic 'Prjt'

Author: Grafiati

Published: 28 June 2021

Last updated: 5 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Prjt.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Londoño-Lázaro, María Carmelina, María Del Pilar Gutiérrez-Perilla, and Paula Andrea Roa-Sánchez. "El papel de las reparaciones en la justicia transicional colombiana: aportes desde una visión teleológica." International Law: Revista Colombiana de Derecho Internacional 15, no. 30 (August 1, 2017): 119. http://dx.doi.org/10.11144/javeriana.il15-30.prjt.

Full text

Abstract:

El reconocimiento e implementación de medidas de reparación se constituye en un aspecto cardinal en las sociedades en transición como la colombiana. El presente artículo se pregunta por el fundamento del deber de reparar a las víctimas de violaciones a los derechos humanos a partir de diversas teorías de justicia, proponiendo una visión teleológica como la más adecuada para lograr las aspiraciones ultimas de una sociedad que busca superar el conflicto y lograr una paz estable y duradera. Este enfoque propone potenciar el papel de las reparaciones de cara a los fines últimos de la justicia transicional, articulando derechos individuales y colectivos, así como condiciones favorables para avanzar en los proyectos de vida personales de las víctimas y de la sociedad en general, a partir de la reivindicación de la noción de bien común. Así pues, se plantea una lógica pluridimensional que rescata tres dimensiones de las reparaciones: individual, colectiva y trascendental. Partiendo de lo anterior, se formulan algunos efectos jurídico-políticos prácticos que resultarían de la aplicación de esta visión teleológica pluridimensional.

APA, Harvard, Vancouver, ISO, and other styles

2

Cárdenas, Julián, Carlos Carranza, Diego Miranda, and Stanislav Magnitskiy. "Effect of GA3, KNO3, and removing of basal point of seeds on germination of sweet granadilla (Passiflora ligularis Juss) and yellow passion fruit (Passiflora edulis f. flavicarpa)." Revista Brasileira de Fruticultura 35, no. 3 (September 2013): 853–59. http://dx.doi.org/10.1590/s0100-29452013000300023.

Full text

Abstract:

Passiflora seeds germinate erratically presenting difficulties for their handling in a greenhouse. The effect of removing of basal point of seeds (RB) and pre-imbibition of seeds of sweet granadilla and yellow passion fruit in 50, 100, 200, and 400 mg mL-1 solutions of gibberellic acid (GA3) or 0.1% KNO3 solution was studied. The experiment was conducted in greenhouses in La Plata, Colombia. Two accessions PrJ1 and PrJ2 of sweet granadilla were evaluated. There were calculated the final percentage of germination (PG), mean germination time (MGT), and the mean germination rate (MGR). The leaf area and dry mass of seedlings were measured 22 days after sowing (das); with this data, specific leaf area and relation root/shoot were calculated. In all cases, the highest germination percentages were achieved treating seeds with KNO3 (89, 92, and 87% for yellow passion fruit, PrJ2, and PrJ1, respectively), but the increase in MGR (3.3 germinated seeds per day) and the decrease in MGT (16 days) were only significant for PrJ1. RB had a significant reduction of PG in all cases (28, 12, and 33% for passion fruit, PrJ2 and PrJ1, respectively). With the increase in the concentration of GA3, PG was reduced for two accessions of sweet granadilla, for yellow passion fruit this trend was not clear, no treatment with GA3 showed significant differences with the control. Leaf area (24.07 cm2) and dry mass of seedlings (135 mg) were significantly higher than seeds previously treated with KNO3 only for PrJ1.The solution of KNO3 0,1% is recommended to improve the germination and initial growth of granadilla seedlings.

APA, Harvard, Vancouver, ISO, and other styles

3

Pimenta, Jorge, Ana Domingos, Pedro Santos, Carla C. Marques, Cátia Cantante, Ana Santos, João P. Barbas, et al. "Is prnt a Pseudogene? Identification of Ram Prt in Testis and Ejaculated Spermatozoa." PLoS ONE 7, no. 8 (August 24, 2012): e42957. http://dx.doi.org/10.1371/journal.pone.0042957.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Lalande, Aude. "Éloge du prêt." Vacarme 32, no. 3 (2005): 17. http://dx.doi.org/10.3917/vaca.032.0017.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Lecerf, Jean-Michel. "Prêt-à-penser." Pratiques en nutrition 15, no. 58 (April 2019): 1. http://dx.doi.org/10.1016/j.pranut.2019.03.001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Lang, Fiona. "Swiss-PROT + TREMBL." Trends in Genetics 13, no. 10 (October 1997): 417. http://dx.doi.org/10.1016/s0168-9525(97)01258-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Heuer, Claudia. "Pret-à-Porter." kma - Klinik Management aktuell 10, no. 04 (April 2005): 28–32. http://dx.doi.org/10.1055/s-0036-1573241.

Full text

Abstract:

Der Verband der Hersteller von IT-Lösungen für das Gesundheitswesen (VHitG) startete im letzten Jahr mit der brancheneigenen Messe ITeG einen ersten Versuchsballon. Offensichtlich traf man damit einen Nerv der Branche. Schon auf der Medica 2004 konnte man Stimmen hören, die sich dafür aussprachen, fortan nur noch die ITeG zur Außendarstellung nutzen zu wollen. So ist denn auch das Interesse an der diesjährigen, zweiten Ausgabe der ITeG gewachsen und es scheint, als hätte die Messe das Potential, sich zu einem echten Branchentreffpunkt zu entwickeln. Dieses Jahr trifft man sich vom 26. bis 28. April 2005 in der Halle 4.0 des Frankfurter Messegeländes.

APA, Harvard, Vancouver, ISO, and other styles

8

Malaro, Marie C. "Anatomie d'un prêt." Museum International (Edition Francaise) 45, no. 2 (April 24, 2009): 51–54. http://dx.doi.org/10.1111/j.1755-5825.1993.tb00557.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Borzeix, Jean-Marie. "Droit de prêt." Le Débat 112, no. 5 (2000): 69. http://dx.doi.org/10.3917/deba.112.0069.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Portes, Richard. "PRêT-à-PORTES." Business Strategy Review 25, no. 4 (November 24, 2014): 14–17. http://dx.doi.org/10.1111/j.1467-8616.2014.01112.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Werner, Sarah. "shkspr prjct (review)." Shakespeare Bulletin 24, no. 1 (2006): 118–21. http://dx.doi.org/10.1353/shb.2006.0020.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

BOUMAN, LISETTE. "TAPIJT VOL PRUT." TvPO 16, no. 4 (August 2021): 46. http://dx.doi.org/10.1007/s12503-021-0864-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Côté, Pierre-Paul. "Considérations sur le prêt commercial et la convention de prêt." Le prêt commercial 28, no. 4 (April 12, 2005): 861–96. http://dx.doi.org/10.7202/042845ar.

Full text

Abstract:

Commercial credit has been given many different forms over the years and the various financial instruments are being constantly refined. By the same token, loan agreements have become increasingly complex documents. The main thrust of this paper is to examine the legal nature, legality and usefulness of a number of financial instruments and clauses usually found in a typical agreement, in the light of basic civil law rules and principles. The first part of this paper deals with a number of financial instruments, namely the open credit agreement, the banker's acceptance, the letter of credit and the letter of guaranty. Secondly the author analyses the typical loan agreement focusing on the convenant 'sfundamentals elements and discussing its relationship with the use of sureties. In particular, two civil law mechanisms that are of some interest in connection with the loan agreement namely novation and subrogation are examined. The third and fourth parts of this paper deal with a number of standard clauses in the open credit and loan agreements.

APA, Harvard, Vancouver, ISO, and other styles

14

Oliveira, S. S., J. dos Santos Nascimento, D. C. Póvoa, S. Amaral Araújo, M. Rodrigues Gamon, and M. C. de Freire Bastos. "Genetic analysis of the bacteriocin-encoding plasmids pRJ6 and pRJ9 of Staphylococcus aureus by transposon mutagenesis and cloning of genes involved in bacteriocin production." Journal of Applied Microbiology 85, no. 6 (December 1998): 972–84. http://dx.doi.org/10.1111/j.1365-2672.1998.tb05261.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Klaushofer, Alex. "Plato pret à porter." Philosophers' Magazine, no. 11 (2000): 57. http://dx.doi.org/10.5840/tpm20001128.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Hardy-Baylé, Marie-Christine. "L’organisme agréé “Prat Psy”." PSN 4, S1 (June 2006): 22–25. http://dx.doi.org/10.1007/bf03027897.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Ogg, Jim. "Le prêt viager hypothécaire." Retraite et société 62, no. 1 (February 1, 2012): 167–73. http://dx.doi.org/10.3917/rs.062.0167.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Clark, D. V. "Molecular and genetic analyses of Drosophila Prat, which encodes the first enzyme of de novo purine biosynthesis." Genetics 136, no. 2 (February 1, 1994): 547–57. http://dx.doi.org/10.1093/genetics/136.2.547.

Full text

Abstract:

Abstract The Drosophila Prat gene encodes phosphoribosylamidotransferase (PRAT), the enzyme that performs the first committed step of the de novo purine nucleotide biosynthesis pathway. Using information from amino acid sequence alignments of PRAT from other organisms, a polymerase chain reaction-based approach was employed to clone Prat. Amino acid sequence alignment of Drosophila PRAT with PRAT from bacteria, yeast, and vertebrates indicates that it is most identical (at least 60%) to the vertebrate PRATs. It shares putative amino-terminal propeptide and iron-binding domains seen only in Bacillus subtilis and vertebrate PRATs. Prat was localized to the right arm of chromosome 3 at polytene band 84E1-2. Owing to the fact that this region had been well characterized previously, Prat was localized to a 30-kilobase region between two deficiency breakpoints. By making the prediction that Prat would have a similar "purine syndrome" phenotype as mutations in the genes ade2 and ade3, which encode enzymes downstream in the pathway, five alleles of Prat were isolated. Three of the alleles were identified as missense mutations. A comparison of PRAT enzyme activity with phenotype in three of the mutants indicates that a reduction to 40% of the wild-type allele's activity is sufficient to cause the purine syndrome, suggesting that PRAT activity is limiting in Drosophila.

APA, Harvard, Vancouver, ISO, and other styles

19

Pavlakis, Nick, David Turner Ransom, David Wyld, Katrin Marie Sjoquist, Rebecca Asher, Val Gebski, Kate Wilson, et al. "Australasian Gastrointestinal Trials Group (AGITG) CONTROL NET Study: Phase II study evaluating the activity of 177Lu-Octreotate peptide receptor radionuclide therapy (LuTate PRRT) and capecitabine, temozolomide CAPTEM)—First results for pancreas and updated midgut neuroendocrine tumors (pNETS, mNETS)." Journal of Clinical Oncology 38, no. 15_suppl (May 20, 2020): 4608. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.4608.

Full text

Abstract:

4608 Background: CAPTEM is an accepted regimen for patients (pts) with advanced pNETs. Single agent 177Lu-Octreotate PRRT is now a standard of care for progressive WHO Grade (G) 1/2 mNETs. High activity was seen with LuTate/CAPTEM in a single arm Phase I/II trial. This study was undertaken to determine the relative activity of adding CAPTEM to LuTate PRRT in pts with mNETs and pNETs. Methods: Non-comparative randomised open label parallel group phase II trial with 2:1 randomisation to PRRT/CAPTEM (experimental arm) vs. PRRT (mNETs control) and CAPTEM (pNETS control). PRRT/CAPTEM: 7.8GBq LuTate day(D) 10, 8 weekly (wkly) x 4, with b.i.d. oral CAP 750mg/m2 D1-14 & TEM 75mg/m2D10-14, 8 wkly x 4; PRRT: 8 wkly x 4; CAPTEM 8 wkly x 4. Primary endpoint: Progression free survival (PFS). mNETS- at 15 months (mo) assuming 15mo PFS 66.4% in control arm, aiming for PFS ³ 80%; pNETS- at 12mo assuming 12mo PFS 60% in control arm, aiming for PFS ³ 75%. Secondary endpoints: Objective tumour response rate (complete or partial) (OTRR), clinical benefit rate (OTRR, stable disease) (CBR), toxicity, quality of life. Results: 75 pts enrolled (Dec 2015 – Nov 2018): mNETs 33 PRRT/CAPTEM and 14 PRRT; pNETS 19 PRRT/CAPTEM and 9 CAPTEM. mNETS: Median follow-up 35mo; 15mo PFS was 90% (95% CI: 73-97%) v 92% (95% CI: 57-99%); OTRR 31% vs 15%; and CBR 97% vs 92% for PRRT/CAPTEM v PRRT respectively. Treatment related adverse events (AEs): 24/32 PRRT/CAPTEM pts had at least one G3 event (75%) vs 5/13 (38%, PRRT); and 4/32 pts at least one G4 event (13%) v 1/13 (8%) respectively, mostly haematologic (haem). Only one patient failed to complete therapy (PRRT/CAPTEM). pNETS: Median follow-up 34mo; 12mo PFS was 76% (95% CI: 48-90%) v 67% (95% CI: 28-88%); OTRR 68% vs 33%; and CBR 100% vs 100% for PRRT/CAPTEM v CAPTEM respectively. Treatment related AEs: 5/18 PRRT/CAPTEM pts had at least one G3 event (28%) vs 3/9 (33%) CAPTEM; 3/18 pts at least one G4 event (17%) v 1/9 (11%) respectively. Conclusions: CAPTEM/PRRT is active, meeting its target landmark PFS for CAPTEM/PRRT (12mo pNETs; 15mo mNETs) with numerically greater OTRR in both pNETs and mNETs, but with more haem toxicity in mNETs. As activity was high in both control arms longer follow up is required to determine if the relative activity of PRRT/CAPTEM is sufficient to warrant Phase III evaluation. Clinical trial information: ACTRN12615000909527 .

APA, Harvard, Vancouver, ISO, and other styles

20

Kim, Yong-Chan, and Byung-Hoon Jeong. "The first report of prion-related protein gene (PRNT) polymorphisms in goat." Acta Veterinaria Hungarica 65, no. 2 (June 2017): 291–300. http://dx.doi.org/10.1556/004.2017.028.

Full text

Abstract:

Prion protein is encoded by the prion protein gene (PRNP). Polymorphisms of several members of the prion gene family have shown association with prion diseases in several species. Recent studies on a novel member of the prion gene family in rams have shown that prion-related protein gene (PRNT) has a linkage with codon 26 of prion-like protein (PRND). In a previous study, codon 26 polymorphism of PRND has shown connection with PRNP haplotype which is strongly associated with scrapie vulnerability. In addition, the genotype of a single nucleotide polymorphism (SNP) at codon 26 of PRND is related to fertilisation capacity. These findings necessitate studies on the SNP of PRNT gene which is connected with PRND. In goat, several polymorphism studies have been performed for PRNP, PRND, and shadow of prion protein gene (SPRN). However, polymorphism on PRNT has not been reported. Hence, the objective of this study was to determine the genotype and allelic distribution of SNPs of PRNT in 238 Korean native goats and compare PRNT DNA sequences between Korean native goats and several ruminant species. A total of five SNPs, including PRNT c.-114G > T, PRNT c.-58A > G in the upstream of PRNT gene, PRNT c.71C > T (p.Ala24Val) and PRNT c.102G > A in the open reading frame (ORF) and c.321C > T in the downstream of PRNT gene, were found in this study. All five SNPs of caprine PRNT gene in Korean native goat are in complete linkage disequilibrium (LD) with a D’ value of 1.0. Interestingly, comparative sequence analysis of the PRNT gene revealed five mismatches between DNA sequences of Korean native goats and those of goats deposited in the GenBank. Korean native black goats also showed 5 mismatches in PRNT ORF with cattle. To the best of our knowledge, this is the first genetic research of the PRNT gene in goat.

APA, Harvard, Vancouver, ISO, and other styles

21

Pavlakis, Nick, David Turner Ransom, David Wyld, Katrin Marie Sjoquist, Rebecca Asher, Val Gebski, Kate Wilson, et al. "First results for Australasian Gastrointestinal Trials Group (AGITG) control net study: Phase II study of 177Lu-octreotate peptide receptor radionuclide therapy (LuTate PRRT) +/- capecitabine, temozolomide (CAPTEM) for midgut neuroendocrine tumors (mNETs)." Journal of Clinical Oncology 38, no. 4_suppl (February 1, 2020): 604. http://dx.doi.org/10.1200/jco.2020.38.4_suppl.604.

Full text

Abstract:

604 Background: Single agent 177Lu-octreotate peptide receptor radionuclide therapy is now a standard of care for progressive mNETS. High activity was seen with LuTate and concurrent CAPTEM chemotherapy in a single arm Phase I/II trial. This study was undertaken to determine the relative activity of adding CAPTEM to LuTate PRRT in patients with mNETs. Methods: Non-comparative randomised open label phase II trial of PRRT +/- CAPTEM in patients with mNETs, with 2:1 randomisation: PRRT /CAPTEM (experimental arm) vs. PRRT (control). PRRT /CAPTEM: 7.8GBq LuTate day(D) 10, 8 weekly (wkly) x 4, with b.i.d. oral CAP 750mg/m2 D1-14 & TEM 75mg/m2 D10-14, 8 wkly x 4, vs. PRRT 8 wkly x 4. Primary endpoint: progression free survival (PFS) at 15 months assuming 15 month PFS of 66.4% in the control arm, aiming for PFS rate > 80%; secondary endpoints: objective tumour response rate (complete or partial response) (OTRR), clinical benefit rate (complete or partial response, stable disease) (CBR), toxicity, and QOL. Results: 47 patients enrolled (Dec 2015 - Feb 2018): 33 PRRT/CAPTEM and 14 PRRT. Two patients withdrew prior to treatment. Patient characteristics were balanced except gender (female 58% vs. 14%). Two patients received 2 prior systemic regimens. After a median follow-up of 32 months, the 15 month PFS was 90% (95% CI: 73-97%) v 92% (95% CI: 57-99%); OTRR 25% vs 15%; and CBR 97% vs 92% for PRRT/CAPTEM v PRRT respectively. For treatment related adverse events 22/32 CAPTEM patients experienced one Grade 3 event (69%) vs 5/13 (38%, PRRT); 4/32 pts experienced one Grade 4 event (13%) v 1/13 (8%) respectively. Only one patient failed to complete therapy due to toxicity (PRRT/CAPTEM). Conclusions: This initial planned analysis demonstrates similarly high 15 month PFS for CAPTEM/PRRT relative to PRRT alone. OTRR is numerically higher but at the cost of greater toxicity. Longer follow up is required to determine if the activity of PRRT/CAPTEM is sufficient to warrant Phase III evaluation. Clinical trial information: ACTRN12615000909527.

APA, Harvard, Vancouver, ISO, and other styles

22

Okuma, Hideyuki, Kentaro Mori, Suguru Nakamura, Tetsuo Sekine, Yoshihiro Ogawa, and Kyoichiro Tsuchiya. "Ipragliflozin Ameliorates Diabetic Nephropathy Associated with Perirenal Adipose Expansion in Mice." International Journal of Molecular Sciences 22, no. 14 (July 8, 2021): 7329. http://dx.doi.org/10.3390/ijms22147329.

Full text

Abstract:

Sodium glucose cotransporter-2 (SGLT2) inhibitors inhibit the development of diabetic nephropathy (DN). We determined whether changes in perirenal fat (PRAT) by a SGLT2 inhibitor ipragliflozin (Ipra) contribute to the suppression of DN development. High-fat diet (HFD)-fed mice were used as a DN model and were treated with or without Ipra for 6 weeks. Ipra treatment reduced urinary albumin excretion (UAE) and glomerular hypertrophy in HFD-fed mice. In the PRAT of Ipra-treated mice, adipocyte size was increased, and inflammation, fibrosis, and adipocyte death were suppressed. In conditioned medium made from PRAT (PRAT-CM) of Ipra-treated mice, the concentration of leptin was significantly lower than PRAT-CM of mice without Ipra treatment. Serum leptin concentration in renal vein positively correlated with UAE. PRAT-CM from HFD-fed mice showed greater cell proliferation signaling in mouse glomerular endothelial cells (GECs) than PRAT-CM from standard diet-fed mice via p38MAPK and leptin-dependent pathways, whose effects were significantly attenuated in PRAT-CM from Ipra-treated mice. These findings suggest that Ipra-induced PRAT expansion may play an important role in the improvement of DN in HFD-fed mice. In vitro experiments suggest that reduced PRAT-derived leptin by Ipra could inhibit GECs proliferation, possibly contributing to the suppression of DN development.

APA, Harvard, Vancouver, ISO, and other styles

23

Alabi, Jaena, Rhonda Huisman, Meagan Lacy, Willie Miller, Eric Snajdr, Jessica Trinoskey, and William Weare, Jr. "By and for Us: The Development of a Program for Peer Review of Teaching by and for Pre-Tenure Librarians." Collaborative Librarianship 4, no. 4 (2012): 165–74. http://dx.doi.org/10.29087/2012.4.4.06.

Full text

Abstract:

Seven pre-tenure librarians at the University Library at Indiana University-Purdue University Indianapolis (IUPUI) created a peer review of teaching (PROT) group. This article provides an overview of the library literature on PROT and identifies the commonalities and variations found in PROT programs. The development, implementation, and benefits of the PROT program at IUPUI are discussed as well as outcomes pertaining to benefits for the observed, the observer, and for the PROT group as a whole. The authors also found that the implementation of a PROT program can enhance the sense of community among colleagues.

APA, Harvard, Vancouver, ISO, and other styles

24

Alabi, Jaena, Rhonda Huisman, Meagan Lacy, Willie Miller, Eric Snajdr, Jessica Trinoskey, and William Weare, Jr. "By and for Us: The Development of a Program for Peer Review of Teaching by and for Pre-Tenure Librarians." Collaborative Librarianship 4, no. 4 (2012): 165–74. http://dx.doi.org/10.29087/2012.4.4.06.

Full text

Abstract:

Seven pre-tenure librarians at the University Library at Indiana University-Purdue University Indianapolis (IUPUI) created a peer review of teaching (PROT) group. This article provides an overview of the library literature on PROT and identifies the commonalities and variations found in PROT programs. The development, implementation, and benefits of the PROT program at IUPUI are discussed as well as outcomes pertaining to benefits for the observed, the observer, and for the PROT group as a whole. The authors also found that the implementation of a PROT program can enhance the sense of community among colleagues.

APA, Harvard, Vancouver, ISO, and other styles

25

Ahlstedt, Jonas, Edvin Johansson, Marie Sydoff, Helena Karlsson, Eddie Thordarson, Magnus Gram, and Olof Eriksson. "Non-Invasive Imaging Methodologies for Assessment of Radiation Damage to Bone Marrow and Kidneys from Peptide Receptor Radionuclide Therapy." Neuroendocrinology 110, no. 1-2 (April 19, 2019): 130–38. http://dx.doi.org/10.1159/000500473.

Full text

Abstract:

Background/Aims: Peptide receptor radionuclide therapy (PRRT) is becoming clinical routine for management of neuroendocrine tumours. The number of PRRT cycles is correlated with treatment effect but theoretically limited by off-target radiation damage to kidneys and bone marrow. New imaging biomarkers for assessment of PRRT tissue damage would enable evaluation of novel renal and bone marrow protective agents, as well as personalised PRRT treatment regiments. Methods: Mice treated with [177Lu]Lu-DOTA-TATE PRRT or vehicle were examined at baseline and following treatment with [18F]fluorothymidine (FLT) positron emission tomography (PET) and technetium-99m-mercapto-acetyl-tri-glycine ([99mTc]Tc-Mag3) single-photon emission tomography (SPECT) to assess dynamic changes in bone marrow proliferation and renal function, respectively. Results: Bone marrow proliferation as assessed by [18F]FLT was decreased 2 days after PRRT treatment, but not vehicle, compared to baseline (target-to-background ratio [TBRmax] baseline:1.69 ± 0.29 vs. TBRmax PRRT: 0.91 ± 0.02, p < 0.01). Renal function as assessed by [99mTc]Tc-Mag3 SPECT was similarly decreased 2 days following PRRT compared to vehicle (fractional uptake rate [FUR] vehicle: 0.030 ± 0.014 s–1 vs. FUR PRRT: 0.0051 ± 0.0028 s–1, p < 0.01). Conclusion: [18F]FLT PET and [99mTc]Tc-Mag3 SPECT are promising techniques for assessing bone marrow and renal injury from [177Lu]Lu-DOTA-TATE PRRT and may potentially improve patient management by allowing evaluation of protective interventions as well as enabling personalised PRRT treatments.

APA, Harvard, Vancouver, ISO, and other styles

26

Jungo, Florence, and Amos Bairoch. "Tox-Prot, the toxin protein annotation program of the Swiss-Prot protein knowledgebase." Toxicon 45, no. 3 (March 2005): 293–301. http://dx.doi.org/10.1016/j.toxicon.2004.10.018.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Párkányi, L., V. Fülöp, M. Czugler, M. Hollósi, M. Zewdu, Z. Majer, and M. Kajtár. "Structure of (3S,9S)-1,7-diazatricyclo[7.3.0.03,7]dodecane-2,8-dithione [cyclo(-Prot-Prot-)]." Acta Crystallographica Section C Crystal Structure Communications 43, no. 12 (December 15, 1987): 2356–58. http://dx.doi.org/10.1107/s0108270187087778.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Siebenhuener, Alexander Rheinhard, Dominique Pretot, and Valerie Treyer. "Outcome analyses in patients with metastatic gastroenteropancreatic neuroendocrine tumors receiving peptide receptor radionuclide therapy with 177Lu-DOTATATE – Impact of treatment order and combination on mortality." Journal of Clinical Oncology 38, no. 15_suppl (May 20, 2020): 4606. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.4606.

Full text

Abstract:

4606 Background: Neuroendocrine tumors of the gastroenteropancreatic tract present heterogeneous with several systemic treatment options in the advanced setting. PRRT with 177Lu-DOTATATE targeting the SSTR-2 receptor of these tumors showed effective responses in the NETTER-1 trial in the short as well as long term follow-up of patients. The aim of our study was to determine the HRQoL and outcome of GEP-NET patients. Methods: 41 GEP-NET patients who received 177Lu-DOTATATE (mean: 3 cycles) between 2012 and 2017 at University Hospital Zurich (USZ) were included in this retrospective analysis. HRQoL parameters (fatigue, insomnia, loss of appetite, abdominal pain, nausea, emesis, diarrhea, weight loss) were assessed before and after treatment. At least 3 weeks after the last PRRT cycle, data on blood parameters, HRQoL, and overall survival data were extracted from patient records. To determine factors influencing the success of PRRT therapy and survival, we recorded pre- and post-PRRT treatments (e.g. selective internal radiation therapy/SIRT, somatostatin analogue therapy/SSA, TKI or chemotherapy) and the time-point of PRRT in the therapeutic sequence was analyzed. Results: Baseline rates of HRQoL and ECOG performance status were assessed (baseline mean: ECOG 0). PRRT was well tolerated, with most patients reporting no significant deterioration in HRQoL after treatment. Blood parameters (hemoglobin, leucocyte and platelet counts, creatinine) and glomerular filtration rate were not significantly affected by PRRT therapy. The number of previous treatments did not influence survival after PRRT; neither did the length of the time period between first diagnosis and PRRT. Patients with a SIRT treatment prior to PRRT had an elevated mortality odds ratio of 4.083. If SIRT was applied to patients with a pancreatic tumor, the mortality odds ratio was 1.33 compared to patients without a pancreatic tumor. Post-PRRT SSA increased the odds for survival, with a mortality odds ratio of 2.33 for patients without SSA after PRRT. Conclusions: Patients with advanced GEP-NETs may benefit from PRRT with 177Lu-DOTATATE, as this treatment appears to be well tolerated and does not significantly impair the HRQoL or symptom load. SIRT before PRRT seems to lower the chances of response and reduces survival instead using this sequence vice versa. This trend was also seen if SSA was not used after PRRT. But these trends have to be proven in prospective trials.

APA, Harvard, Vancouver, ISO, and other styles

29

Buckinx, Fanny, Vincent Marcangeli, Lívia Pinheiro Carvalho, Maude Dulac, Guy Hajj Boutros, Gilles Gouspillou, Pierrette Gaudreau, José Morais, Philippe Noirez, and Mylène Aubertin-Leheudre. "Initial Dietary Protein Intake Influence Muscle Function Adaptations in Older Men and Women Following High-Intensity Interval Training Combined with Citrulline." Nutrients 11, no. 7 (July 22, 2019): 1685. http://dx.doi.org/10.3390/nu11071685.

Full text

Abstract:

Background: This study evaluates whether the initial amount of dietary protein intake could influence the combined effect of high-intensity interval training (HIIT) and citrulline (CIT), or HIIT alone, on body composition, muscle strength, and functional capacities in obese older adults. Methods: Seventy-three sedentary obese older men and women who completed a 12-week elliptical HIIT program with double-blinded randomized supplementation of CIT or placebo (PLA) were divided into four groups according to their initial protein intake (CIT–PROT+: n = 21; CIT–PROT−: n = 19; PLA–PROT+: n = 19; PLA–PROT−: n = 14). Body composition (fat and fat-free masses), handgrip (HSr) strength, knee extensor (KESr) strength, muscle power, and functional capacities were measured pre-intervention and post-intervention. Results: Following the intervention, the four groups improved significantly regarding all the parameters measured. For the same initial amount of protein intake, the CIT–PROT− group decreased more gynoid fat mass (p = 0.04) than the PLA–PROT− group. The CIT–PROT+ group increased more KESr (p = 0.04) than the PLA–PROT+ group. In addition, the CIT–PROT− group decreased more gynoid FM (p = 0.02) and improved more leg FFM (p = 0.02) and HSr (p = 0.02) than the CIT–PROT+ group. Conclusion: HIIT combined with CIT induced greater positive changes than in the PLA groups. The combination seems more beneficial in participants consuming less than 1 g/kg/d of protein, since greater improvements on body composition and muscle strength were observed.

APA, Harvard, Vancouver, ISO, and other styles

30

Kim, Yong-Chan, and Byung-Hoon Jeong. "First report of prion-related protein gene (PRNT) polymorphisms in cattle." Veterinary Record 182, no. 25 (April 17, 2018): 717. http://dx.doi.org/10.1136/vr.104123.

Full text

Abstract:

Prion diseases are caused by structural changes in normal prion protein (PrPC). The prion gene family includes four members: prion protein (PRNP), prion-like protein (PRND), shadow of PRNP (SPRN) and prion-related protein (PRNT). Genetic association studies of prion diseases and the other genes in the prion gene family, except for PRNT, have been performed in cattle. Our previous studies indicated that the distribution of PRNP promoter polymorphisms related with bovine spongiform encephalopathy susceptibility is significantly different in Hanwoo (Korean native cattle) and Holstein cattle. However, PRNT polymorphisms have not been reported thus far in cattle. Hence, we examined the PRNT single nucleotide polymorphisms (SNPs) in 315 Hanwoo and 140 Holstein cattle. We found a total of two SNPs, PRNT c.-87C>T and PRNT c.-37G>C, in the 5’ untranslated region of exon 2. The c.-87C>T and c.-37G>C genotype (P<0.0001) and allele (P<0.0001) frequencies exhibited significant differences in the distribution between Hanwoo and Holstein cattle. In addition, the c.-37G<C polymorphism was not found in Hanwoo. Interestingly, we did not find any polymorphisms in the ORF of bovine PRNT, which is in contrast with the highly polymorphic ovine PRNT ORF region. This is the first genetic research of the PRNT gene in cattle.

APA, Harvard, Vancouver, ISO, and other styles

31

vanLieshout, Tiffany L., Jacob T. Bonafiglia, Brendon J. Gurd, and Vladimir Ljubicic. "Protein arginine methyltransferase biology in humans during acute and chronic skeletal muscle plasticity." Journal of Applied Physiology 127, no. 3 (September 1, 2019): 867–80. http://dx.doi.org/10.1152/japplphysiol.00142.2019.

Full text

Abstract:

Protein arginine methyltransferases (PRMTs) are a family of enzymes that catalyze the methylation of arginine residues on target proteins. While dysregulation of PRMTs has been documented in a number of the most prevalent diseases, our understanding of PRMT biology in human skeletal muscle is limited. This study served to address this knowledge gap by exploring PRMT expression and function in human skeletal muscle in vivo and characterizing PRMT biology in response to acute and chronic stimuli for muscle plasticity. Fourteen untrained, healthy men performed one session of sprint interval exercise (SIE) before completing four bouts of SIE per week for 6 wk as part of a sprint interval training (SIT) program. Throughout this time course, multiple muscle biopsies were collected. We found that at basal, resting conditions PRMT1, PRMT4, PRMT5, and PRMT7 were the most abundantly expressed PRMT mRNAs in human quadriceps muscle. Additionally, the broad subcellular distribution pattern of PRMTs suggests methyltransferase activity throughout human myofibers. A spectrum of PRMT-specific inductions, and decrements, in expression and activity were observed in response to acute and chronic cues for muscle plasticity. In conclusion, our findings demonstrate that PRMTs are present and active in human skeletal muscle in vivo and that there are distinct, enzyme-specific responses and adaptations in PRMT biology to acute and chronic stimuli for muscle plasticity. This work advances our understanding of this critical family of enzymes in humans. NEW & NOTEWORTHY This is the first report of protein arginine methyltransferase (PRMT) biology in human skeletal muscle in vivo. We observed that PRMT1, -4, -5, and -7 were the most abundant PRMT mRNAs in human muscle and that PRMT proteins exhibited a broad subcellular localization that included myonuclear, cytosolic, and sarcolemmal compartments. Acute exercise and chronic training evoked PRMT-specific alterations in expression and activity. This study reveals a hitherto unknown complexity to PRMT biology in human muscle.

APA, Harvard, Vancouver, ISO, and other styles

32

Zemczak, Anna, Paweł Gut, Dariusz Pawlak, Maciej Kołodziej, Leszek Królicki, Beata Kos-Kudła, Marek Ruchała, Grzegorz Kamiński, and Jolanta Kunikowska. "The Safety and Efficacy of the Repeated PRRT with [90Y]Y/[177Lu]Lu-DOTATATE in Patients with NET." International Journal of Endocrinology 2021 (January 23, 2021): 1–10. http://dx.doi.org/10.1155/2021/6615511.

Full text

Abstract:

Purpose. The peptide receptor radionuclide therapy (PRRT) is a treatment option for patients with disseminated, inoperable G1 and G2 neuroendocrine tumours (NETs). The study aims to evaluate the safety, efficacy, and progression-free survival (PFS) of patients after retreatment (R-PRRT) and re-retreatment (RR-PRRT) with tandem isotopes [90Y]Y/[177Lu]Lu-DOTATATE. Material and Methods. Out of 99 treated patients with G1 and G2 NETs, 26 were included in the study and treated with the repeated PRRT (with 5 undergoing the re-repeated PRRT treatment) after an initial positive response to four PRRT cycles and later progression of the disease. [68Ga]Ga-DOTATATE PET/CT and CT/MRI procedures were performed before and after the treatment. Patients were treated with [90Y]Y/[177Lu]Lu-DOTATATE (1 : 1) with mixed amino acid infusion for kidney protection. Toxicity was evaluated using the CTCAE 3.0 criteria. Results. The median follow-up was 88 months (the range: 42–164). The median cumulative administered activity was 22.2 GBq (the range: 17.8–30.7 GBq). Myelodysplastic syndrome occurred in one patient (3.8%), and grade 4 renal toxicity was also detected in one patient (3.8%). No other cases of grade 3 or 4 bone marrow and renal toxicity were observed. The median PFS rate was 31 months after the PRRT and 23 months following the R-PRRT. The OS rate from the diagnosis (OS-d) was 109 months and from the start of the PRRT (OS-t)-92.4 months. During the restaging, 3–6 months after the PRRT, PR, SD, and PD were observed in 19.2%, 80.8%, and 0% of the patients, respectively. After the R-PRRT, PR, SD, and PD were observed in 50%, 42.3%, and 7.7% of the patients, respectively. Conclusions. The repeated therapy with [90Y]Y/[177Lu]Lu-DOTATATE is safe and effective for patients with disseminated, inoperable G1 and G2 neuroendocrine tumours.

APA, Harvard, Vancouver, ISO, and other styles

33

Lung, Mei Sim, Michael Hofman, Grace Kong, Sue-Ping Thang, Michael Michael, and Rodney J. Hicks. "Outcomes of peptide receptor radionuclide therapy (PRRT) in metastatic grade 3 neuroendocrine tumors (NETs)." Journal of Clinical Oncology 35, no. 15_suppl (May 20, 2017): e15694-e15694. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.e15694.

Full text

Abstract:

e15694 Background:Grade 3 (G3) NETs have a poor prognosis and limited treatment options (usually chemotherapy). PRRT is a potential treatment option if all sites of disease demonstrate high uptake on somatostatin-receptor imaging (SSRI). We retrospectively evaluated the efficacy of PRRT in G3 NETs. Methods: We reviewed records of patients with metastatic G3 NETs (Ki-67 > 20%) who received PRRT at our institution. Patients were treated with up to 5 cycles of PRRT, predominantly 177Lu-DOTA-octreotate. Further maintenance PRRT was administered upon progression if deemed suitable on SSRI. Radio-sensitizing chemotherapy was administered unless contra-indicated. Kaplan-Meier estimate was used to determine median overall survival (OS) and median time to new treatment/death (TNTD) defined from start of PRRT. Subgroup-analysis was performed for patients with Ki67 < 55% and ≥55%. Results: 26 patients with metastatic G3 NET received PRRT; 22 combined with chemotherapy (capecitabine/temozolomide (n = 12), 5-fluorouracil or capecitabine (n = 8), other (n = 2)). 58% were male. The median age was 62 (range 16-78 years). 61% had pancreatic NET, 19% small bowel, 8% lung, 8% unknown primary, 4% rectal. 77% had received at least one line of prior chemotherapy. 54% received prior platinum-based chemotherapy. Median follow-up was 33 months (range 8-83 months). Patients received a median of 4 cycles of PRRT (range 1-15). The estimated median OS from start of PRRT was 18 months: for Ki-67 < 55% (n = 21), 20 months; and Ki-67≥ 55% (n = 5), 9 months. The estimated median TNTD was 12 months: for Ki-67 < 55%, 16 months; and Ki-67≥55%, 4 months. 31% of patients were alive without a change in treatment modality following PRRT. Conclusions: In thispoor prognosis G3 NET cohort of whom 77% had received prior chemotherapy, a median OS of 18 months from start of PRRT is encouraging and warrants further study. PRRT is a promising treatment option for patients with G3 NET with high somatostatin-receptor expression selected by SSRI.

APA, Harvard, Vancouver, ISO, and other styles

34

Duke, Joseph W., Amy M. Zidron, Igor M. Gladstone, and Andrew T. Lovering. "Alleviating mechanical constraints to ventilation with heliox improves exercise endurance in adult survivors of very preterm birth." Thorax 74, no. 3 (September 14, 2018): 302–4. http://dx.doi.org/10.1136/thoraxjnl-2018-212346.

Full text

Abstract:

Adult survivors of very preterm birth (PRET) have significantly lower aerobic exercise capacities than their counterparts born at term (CONT), but the underlying cause is unknown. To test whether expiratory flow limitation (EFL) during exercise negatively affects exercise endurance in PRET, we had PRET and CONT exercise to exhaustion breathing air and again breathing heliox. In PRET, EFL decreased and time-to-exhaustion increased significantly while breathing heliox. Heliox had a minimal effect on EFL and had no effect on time-to-exhaustion in CONT. We conclude that aerobic exercise endurance in PRET is limited, in part, by mechanical ventilatory constraints, specifically EFL.

APA, Harvard, Vancouver, ISO, and other styles

35

CURRIE, DOUGLAS C., DOUGLAS A. CRAIG, and JOHN K. MOULTON. "A new genus, Protaustrosimulium, for four species of Australian black flies (Diptera: Simuliidae)." Zootaxa 4521, no. 3 (November 14, 2018): 301. http://dx.doi.org/10.11646/zootaxa.4521.3.1.

Full text

Abstract:

Protaustrosimulium n. gen. is described for four species: two previously named species from southeastern Australia—Paracnephia pilfreyi (Davies & Györkös 1988) and Paracnephia terebrans (Tonnoir 1925)—plus two newly described ones from the southwestern-most corner of Western Australia—Prot. amphorum n. sp. and Prot. opscurum n. sp. Molecular and morphological data suggest a close relationship between members of the new genus and Austrosimulium Tonnoir 1925. Monophyly of Protaustrosimulium is supported mainly by characters of adult females, as two of the four species are known only in that life stage. Two species groups are recognized: the pilfreyi-group for Prot. pilfreyi and Prot. amphorum, and the terebrans-group for Prot. terebrans and Prot. opscurum. The constituent species in each group are distributed vicariously in southeastern and southwestern Australia—a common biogeographical pattern in Australian simuliids.

APA, Harvard, Vancouver, ISO, and other styles

36

Sharon, Haim, Shelly Hagag, and Nir Osherov. "Transcription Factor PrtT Controls Expression of Multiple Secreted Proteases in the Human Pathogenic Mold Aspergillus fumigatus." Infection and Immunity 77, no. 9 (June 29, 2009): 4051–60. http://dx.doi.org/10.1128/iai.00426-09.

Full text

Abstract:

ABSTRACT The role of secreted proteases in the virulence of the pathogenic fungus Aspergillus fumigatus remains controversial. Recently, the Aspergillus niger transcription factor PrtT was shown to control the expression of multiple secreted proteases. In this work, the gene which encodes the PrtT homolog in A. fumigatus was cloned and its function analyzed using a deletion mutant strain. Deletion of A. fumigatus prtT resulted in the loss of secreted protease activity. The expression of six secreted proteases (ALP, MEP, Dpp4, CpdS, AFUA_2G17330, and AFUA_7G06220) was markedly reduced. Culture filtrates from the prtT deletion strain exhibited reduced killing of lung epithelial cells and lysis of erythrocytes. However, the prtT deletion strain did not exhibit altered virulence in lung-infected mice. These results suggest that PrtT is not a significant virulence factor in A. fumigatus.

APA, Harvard, Vancouver, ISO, and other styles

37

Sharma, Rohini, Wai Meng Wang, Joanne Evans, Siraj Yusuf, Adil Al-Nahhas, Francesco Mauri, Tara Barwick, and Eric Aboagye. "68Ga-DOTATATE PET/CT to predict response to peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumours (NETs)." Journal of Clinical Oncology 35, no. 15_suppl (May 20, 2017): 4093. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.4093.

Full text

Abstract:

4093 Background: PRRT represents a step change in NET management, significantly improving survival. However, objective response to PRRT, approximately 20%, is poor. There are no predictive biomarkers of response. Uptake on 68Ga-DOTATATE PET/CT imaging is used to assess patient suitability for PRRT, highlighting the presence of somatostatin receptors (SSTR) to which PRRT selectively binds. We hypothesise that the density of SSTRs, as defined by a minimum SUV uptake, predicts for response to PRRT. Methods: 54 patients underwent PRRT. Modified PERCIST assessment was performed: up to 2 target lesions per organ were identified and volume of interest drawn. Maximum 5 targets were counted. Average SUV (SUVave) was calculated by dividing sum of SUVmax of target lesions by number of lesions. Response was determined by RECIST 1.1. Ki67 and SSTR2 expression were assessed on tumour samples and compared with SUVave. Results: Response to PRRT: partial response (PR) 26%, stable disease (SD) 40% progressive disease (PD) 12%. Response to PRRT predicted progression free survival (PFS) with patients experiencing PR having a PFS 2.5x that of those with SD, and almost 20x as long as PD. Using ROC curve analysis, SUVave of 21.6 predicted for tumour response with high sensitivity (0.74) and specificity (1.0), p = 0.15, 95% CI 0.71-3.96. No association between baseline SUVave and SSTR2 or Ki-67 was observed. SUVave > 21.6 was an independent predictor of clinical outcome. Conclusions: Objective response to PRRT defines a subset of patients with markedly improved PFS. SUVave 21.6 defines a threshold below which patients have a poor response to PRRT. This threshold should be taken forward into prospective study.

APA, Harvard, Vancouver, ISO, and other styles

38

Serra-Prat, Mateu, Pedro Gallo, Albert J. Jovell, Marta Aymerich, and M. Dolors Estrada. "Serra-Prat et al. Respond." American Journal of Public Health 89, no. 1 (January 1999): 111–12. http://dx.doi.org/10.2105/ajph.89.1.111.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Imbert, Claude. "Résistez au prêt-à-penser." Commentaire Numéro41, no. 1 (1988): 17. http://dx.doi.org/10.3917/comm.041.0017.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Cheval, Perrine, Bernard Guzniczak, and Sylvie Vella. "Harmoniser pour mieux prot�ger." Les Cahiers Dynamiques N�74, no. 2 (2018): 42. http://dx.doi.org/10.3917/lcd.074.0042.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Barajas de Prat, José J. "José Juan Barajas de Prat." Hearing, Balance and Communication 13, no. 1 (January 2, 2015): 41–42. http://dx.doi.org/10.3109/21695717.2014.998459.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Guez, Gérard. "Prêt bancaire – accord puis refus." Revue Francophone des Laboratoires 2016, no. 478 (January 2016): 74. http://dx.doi.org/10.1016/s1773-035x(16)30019-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Prat, F. "Questions au Professeur Frédéric Prat." Gastroentérologie Clinique et Biologique 31, no. 8-9 (September 2007): 716–18. http://dx.doi.org/10.1016/s0399-8320(07)91931-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

White, Stephen D. "Etudes clunisiennes. Dominique Iogna-Prat." Speculum 79, no. 4 (October 2004): 1098–99. http://dx.doi.org/10.1017/s0038713400087054.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Gough, N. R. "PRMT Versus Akt for FOXO." Science Signaling 1, no. 44 (November 4, 2008): ec376-ec376. http://dx.doi.org/10.1126/scisignal.144ec376.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

O'Callaghan, José. "Lettre concernant un prêt d'argent." Chronique d'Egypte 70, no. 139-140 (January 1995): 189–92. http://dx.doi.org/10.1484/j.cde.2.308988.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Baum, R. P., J. S�ldner, M. Schm�cking, and A. Niesen. "Peptidrezeptorvermittelte Radiotherapie (PRRT) neuroendokriner Tumoren." Der Onkologe 10, no. 10 (October 2004): 1098–110. http://dx.doi.org/10.1007/s00761-004-0771-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Iogna-Prat, Dominique, Jean-François Dortier, and Emmanuelle Patry. "Entretien avec Dominique Iogna-Prat." Sciences Humaines N° 256, no. 2 (February 1, 2014): 29. http://dx.doi.org/10.3917/sh.256.0029.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Olschewski, H., and K. Bruck. "Thermoregulatory, cardiovascular, and muscular factors related to exercise after precooling." Journal of Applied Physiology 64, no. 2 (February 1, 1988): 803–11. http://dx.doi.org/10.1152/jappl.1988.64.2.803.

Full text

Abstract:

The effect of slightly lowered body temperature on endurance time and possibly related physiological factors was studied in seven male volunteers exercising on a cycle ergometer at an ambient temperature (Ta) of 18 degrees C. Work load was increased to 40% in a stepwise manner (phase I, min 0–16) followed by a period at 80% of peak oxygen consumption (VO2) sustained to exhaustion. On one day, exercise was preceded by a double cold exposure (precooling test, PRET), resulting in a 204-kJ/m2 negative heat storage and a 4 and 0.2 degrees C lower mean skin and core temperature at the start of exercise compared with the control test (CONT). Core temperature dropped further during exercise in PRET. Endurance time at 80% of peak VO2 was increased by 12% (P less than 0.05) in PRET. Heart rate (HR) was decreased throughout PRET (P less than 0.05); oxygen pulse and arteriovenous O2 difference were significantly increased in phase I of PRET, whereas the PRET-CONT differences in stroke volume and cardiac output were not significant. In phase II of PRET (min 16–28, heavy exercise) sweat rate (SR) and heat conductivity, indicating forearm blood flow, were lower (-39%, P less than 0.001; -37%). Pedal rate (PR) was 9% lower (P less than 0.01) in phase II of PRET. At the termination of exercise, PRET-CONT differences in HR, SR, and PR had disappeared.

APA, Harvard, Vancouver, ISO, and other styles

50

Smith, Ashleigh E., Roger G. Eston, Belinda Norton, and Gaynor Parfitt. "A Perceptually-regulated Exercise Test Predicts Peak Oxygen Uptake in Older Active Adults." Journal of Aging and Physical Activity 23, no. 2 (April 2015): 205–11. http://dx.doi.org/10.1123/japa.2013-0213.

Full text

Abstract:

Peak oxygen uptake (V̇O2peak) is reliably predicted in young and middle-aged adults using a submaximal perceptually-regulated exercise test (PRET). It is unknown whether older adults can use a PRET to accurately predict V̇O2peak. In this study, the validity of a treadmill-based PRET to predict V̇O2peak was assessed in 24 participants (65.2 ± 3.9 years, 11 males). The PRET required a change in speed or incline corresponding to ratings of perceived exertion (RPE) 9, 11, 13, and 15. Extrapolation of submaximal V̇O2 from the PRET to RPE endpoints 19 and 20 and age-predicted HRmax were compared with measured V̇O2peak. The V̇O2 extrapolated to both RPE19 and 20 over-predicted V̇O2peak (p < .001). However, extrapolating V̇O2 to age-predicted HRmax accurately predicted V̇O2peak (r = .84). Results indicate older adults can use a PRET to predict V̇O2peak by extrapolating V̇O2 from submaximal intensities to an age-predicted HRmax.

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!